Mannatech (NASDAQ:MTEX – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
13.0% of Mannatech shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 15.0% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Mannatech and Journey Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mannatech | $117.87 million | 0.13 | $2.49 million | ($0.86) | -9.69 |
| Journey Medical | $56.13 million | 3.81 | -$14.67 million | ($0.35) | -22.51 |
Mannatech has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Mannatech has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Mannatech and Journey Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mannatech | 1 | 0 | 0 | 0 | 1.00 |
| Journey Medical | 1 | 1 | 3 | 0 | 2.40 |
Journey Medical has a consensus price target of $12.17, indicating a potential upside of 54.40%. Given Journey Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Journey Medical is more favorable than Mannatech.
Profitability
This table compares Mannatech and Journey Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mannatech | -1.50% | -22.75% | -4.75% |
| Journey Medical | -14.58% | -39.94% | -10.45% |
Summary
Mannatech beats Journey Medical on 8 of the 14 factors compared between the two stocks.
About Mannatech
Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.
About Journey Medical
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Receive News & Ratings for Mannatech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mannatech and related companies with MarketBeat.com's FREE daily email newsletter.
